drugset

drugset / Trial / NCT05933278

Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

NCT05933278 ↗

Phase 2 Completed 150 enrolled PT Bio Farma

NaSingle-groupOpen-labelPrevention

Summary

Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose

Timeline

Start: 2023-07-25
Primary completion: 2024-08-31
Completion: 2024-09-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IndoVac	Vaccine	0.5 ml	Other

Indications